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Copy number variants and indels in 251 families with evidence of X-linked intellectual disability (XLID) were investigated by array
comparative genomic hybridization on a high-density oligonucleotide X chromosome array platform. We identified pathogenic copy
number variants in 10%of families, withmutations ranging from2 kb to 11Mb in size. The challenge of assessing causalitywas facilitated
by prior knowledge of XLID-associated genes and the ability to test for cosegregation of variants with disease through extended pedigrees.
Fine-scale analysis of rare variants in XLID families leads us to propose four additional genes, PTCHD1,WDR13, FAAH2, and GSPT2, as
candidates for XLID causation and the identification of further deletions and duplications affecting X chromosome genes but without
apparent disease consequences. Breakpoints of pathogenic variants were characterized to provide insight into the underlyingmutational
mechanisms and indicated a predominance ofmitotic rather thanmeiotic events. By effectively bridging the gap betweenkaryotype-level
investigations andX chromosome exon resequencing, this study informs discussion of alternativemutationalmechanisms, such as non-
coding variants and non-X-linked disease, which might explain the shortfall of mutation yield in the well-characterized International
Genetics of Learning Disability (IGOLD) cohort, where currently disease remains unexplained in two-thirds of families.Introduction
Intellectual disability (ID) comprises a set of clinically and
genetically heterogeneous disorders in which brain devel-
opment and/or function is compromised. ID is defined
by substantial limitations in both intellectual functioning
and adaptive behavior with onset before the age of
18 years.1,2 ID may be the only consistent clinical feature
(termed nonsyndromic ID) or may present in association
with dysmorphic, metabolic, neuromuscular, or psychi-
atric manifestations (syndromic ID). ID is estimated to
have a prevalence of 1.5%–2% in resource-rich countries
and places a significant demand on healthcare expendi-
ture.3 Nongenetic causes of ID include pre-, peri-, and post-
natal infection and perinatal injury, but chromosomal
aberrations and single gene defects make a substantial
contribution to ID causation.4–7 The identification of caus-
ative mutations in familial or idiopathic ID can contribute
to the clinical management of affected individuals and
their families and can also provide insight into processes
of brain development and function.
The observation that males are more commonly affected
than females, coupled with the identification of ID families
with extended X-linked pedigrees and the relative tracta-
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The Americdiscovery efforts on the X chromosome (recently reviewed
in 8). More than 90 genes have been implicated in syn-
dromic or nonsyndromic forms of X-linked ID (XLID)
and these encompass a wide range of biological functions
and cellular processes (9 and XLMR update website).
Recently, we have reported the results of the large-scale
systematic resequencing of the coding X chromosome in
order to identify novel genes underlying XLID.10 The
coding sequences of 718 X chromosome genes were
screened via Sanger sequencing technology in probands
from 208 families with probable XLID. This resequencing
screen has contributed to the identification of 9 novel
XLID-associated genes but identified pathogenic sequence
variants in only 35/208 (17%) of the cohort families.
Because extensive sequence-based prescreening of known
XLID genes had been performed to enrich for the contribu-
tion of unknown genes to XLID, this figure underestimates
the general contribution of sequence variants to XLID, but
nevertheless highlights that disease remains unexplained
in the majority of cohort families.
The relatively low yield of pathogenic sequence variants
identified by Tarpey et al.10 was surprising and may reflect
both technological and experimental limitations, includ-
ing interpretational difficulties in assigning pathogenicity
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One mutational class that is inefficiently detected by the
direct exon sequencing approach is copy number variation
(CNV). CNVs are operationally defined as genomic
deletions or amplifications, most commonly duplications,
greater than 1 kb in size (variants smaller than 1 kb
are termed indels).11 Genomic duplications are undetect-
able by PCR-based Sanger sequence analysis, which is
nonquantitative, unless the duplication breakpoints occur
within targeted regions, and here the most likely outcome
is failure of PCR amplification. X chromosome deletions
inmales would also result in PCR failure. Although in prin-
ciple itwould be feasible to use failure to amplify as amarker
for CNVdiscovery, in practice it is difficult to systematically
assess PCR failures, whichmay havemultiple causes, in the
context of a large-scale screen in whichmany thousands of
PCR amplicons are obtained from hundreds of samples.
Genomic deletions, duplications, and other structural re-
arrangements have an established role in genetic disease,
including many neurological and neurodevelopmental
disorders.12,13 A number of studies have used whole-
genome microarrays to identify submicroscopic disease-
causing variants in ID and such analysis is increasingly
incorporated into routine clinical practice.14,15 Studies
usingX chromosome tiling path BACarrayswith a reported
resolution of 80–100 kb have also been effectively em-
ployed, identifyingpathogenicCNVs in5%–15%of patient
cohorts.16,17 Critically, the ability of these array platforms
to detect small aberrations is limited: at the time of study
inception, the most feature-dense of the commercially
available oligonucleotide-based whole-genome arrays had
a theoretical sensitivity of 15 kb, although the pace of tech-
nology development in this area is rapid.18
To assess the contribution of genomic rearrangements to
disease in the IGOLD cohort, we developed an X chromo-
some oligonucleotide array with sufficient power to detect
single exon imbalances. Our analysis focused on the iden-
tification and evaluation of low-frequency, high-pene-
trance CNVs as an underlying cause of ID.Material and Methods
Study Cohort
The study cohort consisted of 251 XLID families from Europe, the
USA,Australia, and SouthAfrica. Recruitment criteriawere as previ-
ously described.10 In brief, each family had two ormore cases of ID
in males with a transmission pattern compatible with X-linked
inheritance. Probandshadbeen investigated for cytogenetic abnor-
malities (karyotype at R550 G-band resolution) and FMR1 (MIM
309550) trinucleotide repeat expansion and these had been
excluded as underlying causes of disease. Probands from 200 of
the 251 families had been resequenced by Tarpey et al.10 The cause
of disease in 193 study families (77%)was unknownbut the cohort
also included 46 families with disease that was attributed to
sequence variants and12 familieswithpathogenicCNVs identified
by parallel analyses (Table S1 available online). These families
served as a control group for CNV discovery and interpretation.
Features of the pedigree structure and clinical presentation of
the study cohort are summarized in Table S2. The clinical features174 The American Journal of Human Genetics 87, 173–188, August 1reflect the heterogeneity of ID, with a broad range of ID severity
and a contribution of nonsyndromic and syndromic cases. The
families within the cohort ranged from large extended pedigrees
with many cases of ID to small nuclear clusters.
Array comparative genomic hybridization (aCGH) and subse-
quent experiments were performed on genomic DNA extracted
directly from peripheral blood or from EBV-transformed lympho-
blastoid cell lines (LCLs) via standard methods. CNVs detected in
LCL samples were validated in nontransformed samples in parallel
with the cell line-derived sample. Hybridization experiments
utilized a sample from a single affectedmale in 246 of 251 families.
In the remaining 5 families, there was no available sample from an
affectedmale and so screeningwas performed on a sample from an
obligate carrier female unaffected by ID. All hybridizations were
performed against the male reference sample NA10851, obtained
from the Coriell Cell Repository. To investigate whether selected
CNVs were rare variants that could also be identified in unaffected
individuals, a panel of control samples were employed. Control
DNAs were obtained either from LCLs derived from adults of Euro-
pean ancestry without ID or fromwhite blood cells from voluntary
blood donors. Study protocols were reviewed and approved by
local ethics committees and institutional review boards of each
collaborating institution, and informed consent for research was
obtained for all patients.
Array Design and Hybridization
We employed a custom 385K format Nimblegen oligonucleotide
array with a bipartite design providing both backbone coverage
of the entire X chromosome and targeting coding regions and
phylogenetically conserved elements for high-density probe
coverage (Table S3). Probe coverage achieved a median density of
1 probe per 36 bp in the targeted regions and a median gap size
of 463 bp across theX chromosome backbone design. The oligonu-
cleotide design, array manufacture, DNA labeling, hybridization,
and data normalization were done by the Icelandic Nimblegen
Service Laboratory according to recommended and published
procedures. 2.5 mg of reference and test DNA were labeled with
Cy3 and Cy5, respectively, and cohybridized to the array slides.
The intensity of the two fluorescent dyes was extracted with
NimbleScan software. The Cy3 and Cy5 signal intensities on each
array were normalized to one another via qspline normalization
and a log2 ratio calculated for each probe.
CNV Discovery
CNV discovery was performed with the Aberration Detection
Method 1 (ADM-1) algorithm implemented in CGH Analytics
3.4 software (Agilent) with centralization and fuzzy zero correc-
tions applied.19 Appropriate analysis thresholds were established
with reference to experimental validations (Table S4). Initial
settings were permissive in order to maximize the inclusiveness
of the primary data set and thus the detection of potentially path-
ogenic variants. We subsequently employed more-stringent
sample-level (Figure S1) and CNV-level QC filtering (Figure S2)
to reduce the contribution of false positives to the data set and
define a final data set of rare copy number variants. The CNV
discovery workflow is outlined in Figure S3.
Experimental Validation of CNVs, Breakpoint
Sequencing, and Expression Analysis
Several strategies were employed to validate CNV calls, investigate
segregation of variants within XLID families, and characterize3, 2010
Table 1. Summary of Rare X Chromosome CNVs
All CNVs <1 kb 1–10 kb 10–100 kb 100–500 kb >500 kb
Deletions 498 (440) 182 (161) 224 (202) 86 (71) 4 (4) 2 (2)
Duplication 454 (421) 150 (146) 174 (165) 84 (69) 31 (26) 15 (15)
Total 952 (861) 332 (307) 398 (367) 170 (140) 35 (30) 17 (17)
Total call numbers are stated, with numbers in parentheses indicating the number of distinct CNV loci after merging calls across samples.breakpoints, including standard PCR and bidirectional
sequencing,10 long-range PCR,20 quantitative real-time PCR,21
quantitativemultiplex PCR of short fragments,22 reverse transcrip-
tase PCR,23 fluorescent in situ hybridization,24 X inactivation
analysis,25 and splinkerette PCR.26 Linkage analysis of family
306 was performed via microsatellite marker panels (Applied Bio-
systems) and the Infinium II Human Linkage 12 panel (Illumina)
and analyzed with MERLIN.27 Full details of experimental
methods and primer sequences are available on request.
Bioinformatics Analysis
For bioinformatics analysis, extensive use was made of the UCSC
genome browser and several additional publically available data-
bases including the Database of Genomic Variants, DECIPHER,
Genes2Cognition, HapMart, and GNF SymAtlas. Our analysis
also used the following tools: Blast2, EMBOSS Blast2 (GeeCee,
Fuzznuc, and Palindrome), MFOLD, Primer3, RepeatAround,
RepeatMasker, QGRS Mapper, and Z-hunt Online. All genomic
coordinates correspond to the human genome assembly build 36
(hg18).Results
CNV Discovery
The primary goal of our analysis was to maximize our
detection of potentially pathogenic rare variants. Inform-
ing our analysis settings with experimental validations
(Table S4), the first phase of CNV discovery was at low
stringency and generated a raw data set of 69,582 calls,
of which 33,143 (48%) were deletions and 36,439 (52%)
were copy number gains. To assess the performance of
our array, we investigated whether the nonpseudoautoso-
mal X chromosome CNVs reported by Conrad et al. were
present in our data set.28 Sixty-eight of 107 nonoverlap-
ping CNVs were represented in our cohort. 60% of CNV
positions fell within 500 bp of published estimates and
in only 5% were there discrepancies of breakpoint esti-
mates greater than 5 kb. Reviewing the 39 CNVs that
were absent from our data, 19 were invariant in the Euro-
pean CEU population and 9 CNVs were interrogated
by <5 probes on our array.
Because the first phase of CNV discovery prioritized
inclusiveness over specificity, the data set was compro-
mised by false positive calls and the presence of overlap-
ping calls within ADM-1 estimates. To determine the
extent of the false positive contribution to the data set,
four self-self hybridizations were performed, each with
a different sample. Across the four control experiments,The Americthe median number of CNV calls identified was 39 (range
23–71). For the test hybridizations, the median number
of ADM-1 calls per sample was 205 (range 59–1865), giving
a false positive rate of 19%.
To generate a more stringent data set, we used outlier
analysis to evaluate the performance of probes reporting
a CNV in the context of the sample population, via an
approach similar to Marioni et al.29 This analysis required
the prior exclusion of the poorest-performing samples.
Employing sample-level QC, 24 male samples and all 5
female samples were excluded, representing 12% of the
study cohort but eliminating 29% of the CNV calls gener-
ated via the permissive analysis settings (Figure S3).
Although these excluded sample hybridizations were not
appropriate for high-resolution analysis, some large CNV
calls and potentially pathogenic variants were detected
and experimentally validated in these samples (Table S5).
Overlapping raw CNV calls were condensed to a merged
data set of 16,583 CNV loci and outlier status was assessed
for each locus. This analysis was optimized to capture
highly penetrant rare variants and therefore only CNVs
with a frequency of <5% were retained. The data set was
further reduced to exclude two samples generating an
excessive number of apparent calls that were unexplained
(Figure S3). The final data set of 952 rare CNVs, corre-
sponding to 861 distinct CNV loci identified in 220 male
XLID samples, is summarized in Table 1 and listed in
Table S6. The mean number of rare variants per individual
was 4.3 (range 0–23). The number of copy number losses
(498) and gains (454) were broadly similar, with deletions
slightly in excess at the smaller size scale and copy number
gains dominating in the larger size categories. 332/952
(35%) CNVs were intergenic and a further 139 CNVs
(15%) were contained entirely within introns. The detec-
tion of coding variants is skewed by the bias toward array
coverage of these regions and 50% of rare CNVs were esti-
mated to have some coding sequence overlap, although in
some cases this overlap is minimal andmay reflect errors in
CNV size estimation.
Experimental Validations and Sources of Array Noise
A subset of CNV calls were experimentally validated by
PCR spanning the putative CNV boundaries or by qPCR
(Table S7). 40/52 CNV loci were confirmed as deletions
or duplications and 7/52 were false positives. Although
a proportion of this noise is unexplained, 7 of 12 copy
number false-positive calls were associated withan Journal of Human Genetics 87, 173–188, August 13, 2010 175
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Figure 1. Single-Nucleotide Variants Can Effect Probe Hybridization
(A) Population distribution of mean log2 ratio for six probes overlying the ZDHHC9 IVS1þ5G > C point mutation found in a single
family.
(B) Relative location of probes and point mutation.
(C) Population distribution of mean log2 ratio for six probes overlying common SNP rs1329546.
(D) Relative location of probes and SNP.underlying sequence variation. We found that single-
nucleotide variations could be sufficient to disrupt probe
hybridization and to generate artifactual CNV calls where
this disrupts a number of overlapping or contiguous
probes. The effects of a common SNP and a rare sequence
variant on hybridization log2 ratio are shown in Figure 1.
Most commonly, sequence variants result in artifactual
deletion calls but, rarely, duplication calls were also found
to be due to single-nucleotide sequence variants in the test
sample.
To assess the extent to which SNP-related artifacts
confound array analysis, we considered a set of 15
common SNPs that were targeted by five or more probes
and where we had previously obtained genotype informa-
tion by exon resequencing (Table S8). Genotypes at 8 of 15
common SNPs were significantly associated with the
average log2 ratio of all overlying probes. In some cases
the effect on log2 is minimal, but in 2/15 cases CNVs
were called in samples at the extremes of the distribution.
CNVs Affecting Known XLID Genes
One goal was to identify directly pathogenic deletions and
duplications down to the scale of single exon abnormali-176 The American Journal of Human Genetics 87, 173–188, August 1ties. In assessing the relevance of a CNV to ID it was neces-
sary to consider both the likely consequence of the CNV
on gene structure and function and also, given the extent
of benign structural variation, whether the gene(s) are of
likely relevance to ID. CNVs were prioritized for detailed
evaluation on the basis of (1) overlap with known ID-asso-
ciated genes, (2) predicted disruption of coding sequence,
and (3) not reported in studies of individuals with normal
cognitive abilities.
In sum, we detected 25 likely pathogenic CNVs (18
duplications and 7 deletions) affecting known ID-associ-
ated genes (Table 2). Twelve of these pathogenic CNVs
had previously been identified and were included for
control purposes and, in some cases, to refine the bound-
aries of the rearrangement. The structural variants ranged
from 2 kb to >11 Mb in size and varied in content from
alterations affecting a single exon to those affecting several
genes. PCR or FISH confirmation of these variants was per-
formed, together with segregation analysis where familial
samples were available and mRNA expression analysis
where appropriate. Clinical summaries of the families
and pedigrees with confirmed variant segregation data
are in Table 2 and Figure S4, respectively.3, 2010
Table 2. Likely Pathogenic CNVs Affecting Known ID-Associated Genes
CNV Clinical Presentation
Family Type Gene(s) Genomic Coordinatesa Cytoband
Extent
(kb) XIb
ID
Severity S/NSc Reference
57 Dup
þTrip
several, including MECP2 Dup:152 786 182-153 278 914 (E)
Trip:152 953 000-153 218 000(M)
Xq28 492 nd severe S
164 Dup several, including MECP2 152 021 972-153 401 219 (E) Xq28 1379 nd severe S 42,79 K8300
185 Dup several, including MECP2 152 487 808-153 062 828 (M) Xq28 575 nd severe S 42,79 K8210
241 Dup several, including MECP2 152 824 478-153 167 906 (E) Xq28 343 nd severe S
340 Dup several, including MECP2 152 575 696-153 262 980 (E) Xq28 687 4:96 severe S 80 family 1
344 Dup several, including MECP2 152 788 677-153 287 392 (E) Xq28 499 1:99 severe S -
389 Dup several, including MECP2 152 780 000-153 220 753 (M) Xq28 441 nd severe S -
495 Dup several, including MECP2 152 466 800-154 426 868 (M) Xq28 1960 10:90 severe S 80 family 2
509 Dup
þTrip
several, including MECP2 Dup:152 757 505-153 246 869 (E)
Trip:153 183 000-153 218 000 (M)
Xq28 489 nd severe S -
77 Dup several, including HUWE1
and HSD1710B
53 240 015-53 999 700 (E) Xp11.22 759 nd moderate N 81
304 Dup several, including HUWE1
and HSD1710B
53 409 042-53 786 049 (E) Xp11.22 377 nd moderate N 81
359 Dup several, including HUWE1
and HSD1710B
53 004 979-53 729 979 (E) Xp11.22 715 nd moderate N 81
538 Dup several, including HUWE1
and HSD1710B
53 232 828-54 256 595 (E) Xp11.22 1024 2:98 moderate N
376 Dup several, including RPS6KA3,
MBTPS2, and SMS
18 985 933-22 751 175 (E) Xp22.13-
Xp22.11
3765 8:92 moderate N
317 Dup several, including GRIA3 119 698 636-125 699 533 (S) Xq24-Xq25 6001 nd moderate
422 Dup several, including MED12,
NLGN3, SLC16A2, KIAA2022,
ATRX, and BRWD3
70 134 868-81 653 582 (E) Xq13.1-q21.1 11519 nd severe S
505 Dup ARX, POLA1 (partial) 24 902 835-24 943 900 (S) Xp21.3 41 12:88 moderate N
110 Dup AFF2 (partial) 147 547 319-147 757 141 (S) Xq28 210 nd mild N
32 Del IL1RAPL1 (partial) 28 939 863-29 497 216 (E) Xp21.3-21.2 557 46:54 moderate N
121 Del Il1RAPL1 (partial) 28 922 932-29 253 959 (S) Xp21.3 331 nd moderate N
398 Del SLC16A2 (partial) 73 666 964-73 669 304 (S) Xq13.2 2 48:52 severe N
399 Del SLC16A2 (partial) 73 552 449-73 567 609 (S) Xq13.2 15 18:82 severe N
115 Del SLC9A6 (partial) 134 934 236-134 943 268 (E) Xq26.3 9 48:52 severe
147 Del MAOA and MAOB (partial) 43 426 228-43 666 586 (S) Xp11.3 240 41:59 severe N
506 Del CUL4B (noncoding) 119 578 701-119 584 448 (S) Xq24 6 nd moderate N
a Letters in parentheses after genomic coordinates specify whether CNV bounds are ADM-1 estimates (E) or have been adjusted after breakpoint sequencing (S) or
qPCR and manual inspection of probe log2 ratios (M).
b X inactivation status (percentages of each allele in an obligate female carrier).
c S, syndromic; N, nonsyndromic; further information on clinical presentation is available on request. nd, not determined.Sixteen families had duplications >100 kb that are
considered to cause disease as a consequence of altered
dosage of intact genes, although there may be some contri-
bution from disrupted genes, particularly close to the
duplication boundaries. Of these, nine families had Xq28
duplications, which included MECP2 (MIM 300005), and
four families had duplications on Xp11.22 including the
HUWE1 (MIM 300697) and HSD17B10 (MIM 300256)
genes. These two ‘‘hotspots’’ of duplication contained largeThe Americcommon regions of overlap (238 kb forXq28 and 321 kb for
Xp11.22), but thebreakpoint coordinatesof each rearrange-
ment were different. A recent study ofMECP2 duplications
emphasized the occurrence of rearrangement complexity
in one quarter of cases.30 In keeping with this finding,
two of nineMECP2-containing duplications had segments
of triplication embedded within the duplicated region.
The three remaining large duplications affecting
multiple genes were each found in a single family.an Journal of Human Genetics 87, 173–188, August 13, 2010 177
A 3.8 Mb duplication of Xp22.11-p22.13 was detected
in family 376. This region contains 18 RefSeq genes, of
which 3 are known XLID-associated genes (RPS6KA3
[MIM 300075], MBTPS2 [MIM 300294], and SMS [MIM
300105]) and 3 (SH3KBP1 [MIM 300374], PDHA1 [MIM
300502], and CNKSR2 [MIM 300724]) are orthologs of
mouse postsynaptic density (PSD) components (Genes2-
Cognition database). The duplicated region overlies a
smaller duplicated region reported in DECIPHER (case
00249293). Family 317 has a 6 Mb duplication containing
the cancer testis antigen CT47 cluster (MIM 300780-90)
and a further 9 RefSeq genes, of which only GRIA3 (MIM
305915) has a known association with XLID and is also
a PSD component. Family 422 has an 11.5 Mb duplication
containing 70 RefSeq genes, including the XLID-associated
genes MED12 (MIM 300188), NLGN3 (MIM 300336),
SLC16A2 (MIM 300095), KIAA2022 (MIM 300524), ATRX
(MIM 300032), and BRWD3 (MIM 300553).
Two further duplications were identified that are pre-
dicted to disrupt expression levels or function of a single
XLID-associated gene. In family 505, a 41 kb duplication
extending from the terminal exon of POLA1 (MIM
312040) across the entire coding sequence of ARX (MIM
300382) was identified. The duplication was maternally in-
herited and not present in an unaffected brother. The
duplication was in direct tandem orientation, but the
absence of ARX expression in available tissue material
precluded further dissection of the cellular consequences
of the rearrangement. In family 110, a 210 kb region
including exons 3–7 of AFF2 (MIM 300806) were found
to be duplicated. The direct tandem orientation of the
duplicated segment is predicted to introduce a premature
termination codon into the transcript or to trigger aberrant
splicing, but experimental verification of this was not
possible because of the absence of AFF2 expression in avail-
able tissues.31 Segregation studies revealed that the dupli-
cation was absent from the youngest of three brothers,
all of whom were considered to be affected.
The seven deletions likely to be pathogenic included two
families with intragenic deletions of IL1RAPL1 (MIM
300206) (families 32 and 121), two single exon deletions
within SLC16A2 (MIM 300095) (families 398 and 399),
and one intragenic deletion of SLC9A6 (MIM 300231)
(family 115). In each case, the clinical presentation was
compatible with published reports of loss-of-function
sequence variants in these genes.32–34 In family 147, we
identified a 240 kb deletion that eliminated the function
of both monoamine oxidase genes (MAOA [MIM 309850]
and MAOB [MIM 309860]) without affecting the adjacent
Norrie’s disease gene (NDP [MIM 300658]), permitting
further dissection of the phenotype associated with mono-
amine oxidase dysfunction.20
We were also able to ascribe pathogenicity to a 2 kb non-
coding deletion in family 506 that disrupts the 50UTR of
the widely expressed CUL4B (MIM 30304) isoform 2
(Figure 2A). The deletion cosegregated with disease
(Figure 2B), and qPCR analysis of mRNA from patient178 The American Journal of Human Genetics 87, 173–188, August 1LCLs revealed a complete loss of CUL4B expression (Fig-
ure 2C). This is one of several noncoding variants in prox-
imity to the coding sequences of XLID-associated genes.
Some noncoding variants, such as the intronic 5 kb
IL1RAPL1 deletion in family 329, could be discounted
because of the presence of more convincing causative
variants, in this case a CUL4B sequence variant.23 There
remain other noncoding variants where the significance
remains unclear; examples include the 9 kb intronic dele-
tion of NLGN4X (MIM 300427) in family 126 and the
182 kb duplication of PCDH11X (MIM 300246) intronic
sequence in family 335 (Table 3).Identification of Novel XLID Genes
In addition to affecting known XLID-associated genes,
some CNVs may disrupt genes not previously known to
cause XLID. Here, the key challenge is to distinguish clin-
ically significant and thus pathogenic CNVs from benign
but rare variation. We used several criteria to assess likely
significance: (1) cosegregation of CNV with disease within
the pedigree; (2) absence of CNV from public databases
and control populations; and (3) expression pattern and
predicted gene function compatible with neurological
disease. There were four genes (PTCHD1, WDR13 [MIM
300512], FAAH2 [MIM 300654], and GSPT2 [MIM
300418]) that met these criteria and warrant further anal-
ysis (Figure 3 and Table 4).
A 90 kb deletion spanning the entire PTCHD1 gene was
identified in family 540. Intragenic deletions removing
multiple exons were detected in WDR13 (family 206) and
FAAH2 (family 494). In LCLs from affected males in family
494, who lack FAAH2 exons 9 and 10, two misspliced
FAAH2 transcript species were detected: exon 8 spliced to
exon 11 and exon 7 spliced to exon 11. BothmRNA species
introduce frame shift mutations and are predicted to
disrupt the amidase domain.
In family 463, we identified a whole-gene duplication of
GSPT2 and confirmed the direct tandem orientation of the
duplicated region.Analysis of a Retrotransposition Event
Family 306 was found to have a duplication corresponding
to the coding exons only of LUZP4 (MIM 300616)
(Figure 4). The presence of an insertion of the LUZP4 tran-
script, consistent with a retrotransposition event, was
confirmed by PCR amplification and sequencing of the
spliced transcript from genomic DNA template in the
proband. The inserted LUZP4 copy cosegregated with
disease through the pedigree. Splinkerette PCR to identify
the sequence flanking the insertion revealed that the retro-
transposed copy was embedded in intron 5 of the IQCE
gene on chromosome 7p22.2. Microsatellite and SNP
markers flanking the insertion site also segregated in
a manner consistent with the retroinsertion data. No retro-
transposed copy of LUZP4 was detected in 450 control
males. Furthermore, linkage analysis via microsatellites3, 2010
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Figure 2. A Noncoding Deletion Eliminates CUL4B Expression
(A) UCSC genome browser snapshot showing 6 kb deletion location relative to CUL4B RefSeq transcripts, repetitive elements, and
regions with regulatory potential and vertebrate conservation.
(B) Cosegregation of deletion and disease in family 506 could be tested in only a subsection of the extended X-linked pedigree because of
limited sample availability. Arrow indicates individual analyzed by aCGH.
(C) qPCR analysis indicates absence of CUL4BmRNA, but not control CUL4A transcript, in patient LCLs relative to a wild-type control.
Expression analysis was performed as described in Kerzendorfer et al.78 with Applied Biosystems TaqMan gene expression assays
Hs00757716_m1 (CUL4A) and Hs00186086_m1 (CUL4B).and SNPs excluded the nonpseudoautosomal X chromo-
some from association with disease in this pedigree.
Variants Not Associated with Disease
Segregation studies allowed us to exclude a primary role in
disease causation for a number of CNVs, some of whichTable 3. Experimentally Verified CNVs of Unknown Significance or Ex
Family
CNV
Type Genomic Coordinatesa
Extent
(kb) Genes
126 Del 6 027 992-6 037 317 (S) 9 NLGN4X (noncodin
335 Dup 91 132 100-91 314 578 (E) 182 PCDH11X (noncodi
329 Del 28 779 866-28 784 639 (E) 5 IL1RAPL1 (noncodin
62 Del 69 363 478-69 378 892 (M) 15 AWAT1
10 Dup 148 156 928-148 867 255 (E) 710 several including ID
93 Dup 122 797 004-123 203 499 (E) 406 XIAP and STAG2
93 Dup 134 077 508-134 635 763 (E) 558 CXorf48, ZNF75,
ZNF449, DDX26B
507 Dup 514 451-1 394 128 (E) 880 SHOX, CRLF2, CSF2
25 Dup 2 128 149-2 498 028 (E) 370 DHRSX, ZBED1
a Letters in parentheses after genomic coordinates specify whether CNV bounds ar
qPCR and manual inspection of probe log2 ratios (M). Pedigrees and CNV segreg
The Americwould appear a priori to be good candidates for XLID asso-
ciation. Cautious interpretation of cosegregation data is
required because ID is sufficiently common for phenocop-
ies to exist within families. Consequently, the presence of
a variant in an unaffected male is more compelling
evidence that the variant does not cause disease than notcluded from Disease Causation by Segregation Analysis
Present in DGV?
Cosegregates
with Disease? Comments
g) no yes (limited pedigree)
ng) no possibly (absent from
mildly affected female)
g) no nd pathogenic CUL4B
mutation in family
no no pathogenic UPF3B
mutation in family
S no (partial overlap) no
no (partial overlap) no
no (partial overlap) no
RA no (partial overlap) no
no (partial overlap) no
e ADM-1 estimates (E) or have been adjusted after breakpoint sequencing (S) or
ation data in Figure S5. nd, not determined.
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Figure 3. Cosegregation of CNVs and
Disease for Putative Novel XLID Genes
Arrows indicate the individual subjected
to aCGH analysis. Genotypes of all tested
individuals are reported with alleles
described as WT (wild-type), del (deletion),
or dup (duplication).
(A) Family 540, PTCHD1 deletion.
(B) Family 494, FAAH2 intragenic deletion.
(C) Family 206, WDR13 intragenic dele-
tion.
(D) Family 463, GSPT2 duplication.finding the variant in an affected male. CNVs that failed to
cosegregate with disease are listed in Table 3, with accom-
panying segregation data in Figure S5. For example, a
710 kb duplication encompassing the IDS (MIM 309900)
gene was identified in family 10. Loss of function of IDS
causes Hunter Syndrome, a lysosomal storage disease,
which can have central nervous system manifestations,
and a similar duplication has been proposed as potentially
significant in an autistic spectrum disorder (ASD) study.35
In this study, we can discount the variant from disease
causation as indicated by the fact that it is absent from
an affected male (III:3) and obligate female carrier (II:4)
and present in an unaffected male (II:2).Table 4. Candidate Novel XLID-Associated Genes
Family CNV Type Genomic Coordinatesa
Genomic
Extent (kb) Genes Present in DG
540 Del 23 239 008-23 329 210 (S) 90 PTCHD1 no
206 Del 48 345 024-48 348 048 (S) 3 WDR13 no: overlaps sin
of large variant
494 Del 57 487 858-57 493 349 (E) 5 FAAH2 no
463 Dup 51 469 871-51 509 041 (S) 39 GSPT2 no
a Letters in parentheses after genomic coordinates specify whether CNV bounds are ADM-1 estimates (E) or ha
qPCR and manual inspection of probe log2 ratios (M).
b GNF symatlas data.
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of genes, totalling approximately 1%
of all X chromosome genes, which
were deemed nonessential on the
basis of the presence of polymorphic
truncating variants or other null vari-
ants, which failed to cosegregate with
a disease phenotype and were found
in clinically normal individuals. In
this study, we identified an additional
gene that may not be required for
normal existence or cognitive func-
tion: AWAT1, an acyl-CoA wax
alcohol acyltransferase that functions
in lipid esterification.36 The proband
in family 62 has a deletion encom-
passing the entire AWAT1 gene. Thisinherited deletion does not cosegregate with disease, in
contrast to a truncating sequence variant in UPF3B muta-
tion to which XLID causation has been attributed.37
Adopting a model often applied in complex disease
studies, a number of recent reports have identified
sequence or copy number variants at elevated frequencies
in neuropsychiatric disease cases relative to controls and
have suggested that these variants may have reduced pene-
trance, modify the clinical presentation, or function as risk
factors, predisposing to disease but not sufficient in them-
selves to cause disease.38,39 These variants may be found in
combination with other deleterious variants or do not
cosegregate fully with disease as in the case of the TSPAN7V?
Present in
Controls?
Brain
Expressionb?
0/447 yes
gle report
(7789)
0/615 yes
0/450 yes
0/181 yes
ve been adjusted after breakpoint sequencing (S) or
chrX (Mb):
LUZP4
A
114.42 114.43 114.44 114.45 114.46
1.2
1
0.8
0.6
0.4
0.2
0
-0.2
-0.4
-0.6
-0.8
Log2 
Ratio
I:1
WT
II:1
III:1
INS
I:2
INS
II:2
INS
III:2
II:3
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III:3
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III:4
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II:7
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II:8
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Figure 4. Retroinsertion of LUZP4
(A) Increased log2 ratios were observed for
LUZP4 exonic probes (highlighted by red
arrows) but not for surrounding noncod-
ing regions. Scatter plot shows individual
probes, solid line shows six probe sliding
average.
(B) The retroinsertion (INS) is found in all
three affected males and was inherited
from their mothers. Both unaffected males
did not have the retroinsertion (WT). The
arrow indicates the individual analyzed
by aCGH. Colored bars summarize non-
pseudoautosomal X chromosome microsa-
tellite and SNP linkage data and reveal no
common region of haploidentity between
the three affected males.duplications identified by Froyen et al.16 CNVs identified
in the IGOLD cohort that have been purported to have
disease associations, either in ID or ASD or schizophrenia
cases, are detailed in Table S9. Interpretation of the signif-
icance of these findings will require deep analyses with
cohorts and matched controls at least an order of magni-
tude larger than the present study.
Cohort Comparisons
The utility of comparison to control data sets, such as those
collated in the Database of Genomic Variants, is limited by
the small number of studies that have captured rare X
chromosome structural variants at a comparable resolu-
tion. Instead, to assess whether there is evidence for the
contribution of unidentified CNVs to disease, we per-
formed intrastudy comparisons of CNV burden betweenThe American Journal of Human Gfamilies where the cause of disease
has been identified to those families
where the cause of disease remains
unidentified (Table 5). The rare CNV
burden of families with pathogenic
point mutations compared to those
with no identified cause of disease is
broadly similar.
We also compared the clinical
features of cases in which ID-causing
mutations have been identified to
those in which the basis of disease
causation remains unknown (Fig-
ure S6). Overall, pathogenic muta-
tions, i.e., sequence variants (point
mutations and small indels) and
CNVs, have been identified in 30%
of families with >3 affected males
compared to 19% of sibling pairs. In
general, ID was more severe in cases
with structural rearrangements com-
pared to those with pathogenic
sequence variants or unknown dis-
ease causation. This finding is likelyto be skewed by the high number of probands with
MECP2 duplications detected in the cohort, all of whom
have a severe phenotype. In other respects, the pathogenic
CNV and sequence variant subgroups were similar. For
example, epilepsy, neurological involvement, and dysmor-
phism were found in a similar proportion of families with
pathogenic CNVs and sequence variants and at levels
slightly higher than in the unresolved families.
Breakpoints and Rearrangement Mechanisms
Analysis of CNV junction sequences and features of the
local genomic architecture can provide insight into the
mechanism of CNV formation. In some genomic disorders,
the critical region is flanked by highly homologous low-
copy repeats (LCRs), which can mediate nonallelic homol-
ogous recombination (NAHR), resulting in recurrentenetics 87, 173–188, August 13, 2010 181
Table 5. Comparison of CNV Burden in XLID Cohort Subdivided by Cause of Disease
Disease Attributed
to CNV (n ¼ 23)
Disease Attributed to
Sequence Variant (n ¼ 43)
Cause of Disease
Unknown (n ¼ 154)
Number of rare variants Deletions 54 (2.3) 86 (2.0) 358 (2.3)
Duplications 63 (2.7) 82(1.9) 309 (2.0)
Total 117 (5.1) 168 (3.9) 667 (4.3)
Mean extent of rare variants (kb) Deletions 27.3 11.7 7.8
Duplications 306.2 26.2 39.2
Total 177.5 18.8 22.4
Only samples that passed QC for high-resolution analysis were compared (n ¼ 220). Numbers in parentheses indicate mean values per sample.deletion or duplication of the intervening DNA
segment.24,40,41 LCRs and genomic architecture have also
been associated with nonrecurrent rearrangements, partic-
ularly those in which some breakpoint grouping is
apparent, such as MECP2 and PLP1 duplications.30,42–44
However, although global surveys of CNV genomic distri-
bution in clinically normal populations suggest an associa-
tion between CNV-rich regions and segmental duplica-
tions, pathogenic rearrangements often consist of rare
nonrecurrent CNVs with no association with LCRs.45–49
In some cases there may be underlying sequence features,
such as the presence of repetitive elements or non-B DNA
structure-associated sequences (reviewed in 50), which
may confer genomic instability.42,49,51
We obtained junction sequences for 12 pathogenic
CNVs (8 deletions and 4 duplications). Alignments of
breakpoint sequences are provided in Figure S7 and
their key characteristics are summarized in Table S10.
All sequenced rearrangement events were simple, with
intronic or intragenic breakpoints. Nine of 12 breakpoints
had microhomology of 2–9 bp, two had a single nucleo-
tide that could have been derived from either breakpoint,
and one appeared to be a blunt-ended join with no mi-
crohomology. In addition to microhomology at the dele-
tion breakpoint in family 206, a 12 bp duplication was
detected that could be explained by a serial replication
slippage event. Each of the four sequenced duplication
events were found to be tandem and directly orientated.
This arrangement was also suggested by FISH character-
ization of the duplication in family 376, one of four
cases where no junction sequence was obtained by PCR
approaches. The other two cases where the junction
sequence was not identified were deletions in families
115 and 494. In both cases, analysis of mRNA confirmed
that the orientation of exons flanking the deletion was
unaltered, and PCR amplicons just outside the deletion
breakpoints were successfully amplified. In combination,
these results suggest that the failure to obtain junction
PCR products in these cases may reflect the presence of
short sequences refractory to PCR or more complex
rearrangements with additional novel sequence at the
breakpoint.182 The American Journal of Human Genetics 87, 173–188, August 1Ten of 12 breakpoint regions had either unilateral or
bilateral involvement of repetitive elements, but in no
case was the class of repeat shared between breakpoint
pairs and no significant sequence similarity between
any breakpoint pairs was detected by Blast2 analysis.
Furthermore, no significant enrichment of specific repeat
elements or LCRs was detected (Table S11). We also evalu-
ated the recombination and breakpoint-associated motifs
listed by Abeysinghe et al.52 but found no significant over-
representation of any of these motifs (data not shown).
However, we did detect significant enrichment of GC
content in breakpoint regions compared to a simulated
data set of 500 random X chromosome 150 bp sequences.
The mean GC content of breakpoint regions was 47%,
compared to 39% in controls (two-tailed t test, t ¼ 4.059,
p < 0.001). Non-B DNA-associated structures such as
G-quartet and Z-DNA were also found at elevated
frequency (p < 0.05).
Breakpoint sequencing also enabled us to assess array
performance in terms of both the precision of the ADM-1
array estimates and probe performance. Despite the
position of breakpoints in noncoding regions, which
had a median spacing of 1 probe per 515 bp, 21 of 24
sequenced breakpoints fell within 1 kb of the array esti-
mates. Analysis of sequence-characterized events also
revealed that log2 ratio deviations in deletions were
reported more strongly than duplications, in part reflect-
ing the greater impact of a change from 1 to 0 copies (in
a male deletion) compared to moving from 1 to 2 copies
(in a male duplication). For example, whereas 85% of
probes with a deletion had a log2 value of <0.25 (with
70% <0.5), only 73% of probes in duplications attained
log2 values of more than 0.25 (with 48% >0.5). Although
we did not sequence Xq28 duplication breakpoints, qPCR
was used to validate array estimates of duplication extent
and copy number state. In six of nine cases, there was
good agreement between previous analyses, estimated
array bounds, and qPCR data, but in three cases the extent
of the duplication is underreported (families 185, 495, and
389). The discrepancies here are more extensive than for
other evaluated CNVs and may reflect the notoriously
complex architecture and sequence variation in Xq28.3, 2010
Discussion
We report the investigation of X chromosome copy
number variation in a cohort of individuals with familial
intellectual impairment suggestive of X-linked disease.
The use of a custom-designed X chromosome-specific
high-density oligonucleotide array enabled us to obtain
high-resolution and targeted coverage of functional
regions of the genome down to the resolution of a single
exon while maintaining sufficient coverage of the noncod-
ing X for accurate definition of rearrangement boundaries,
aiding interpretation and downstream analysis. We could
confidently assign pathogenicity to CNVs on the X chro-
mosome in 25 cases, which corresponds to 10% of the
cohort (pathogenic variants were detected in 25/251
sample hybridizations and 23/220 samples analyzed at
high resolution). This is higher than the 5% reported by
Froyen et al.16 because of the combination of higher reso-
lution of the analysis platform and selection of familial
cases. The breakpoints of the deletions and duplications
were accurately predicted from the array analysis, which
facilitated rapid confirmations of CNVs or indels by inde-
pendent methods such as FISH or qPCR. On the basis of
this, the beneficial use of higher-resolution array CGH is
clear. With the advent of higher probe capacity for
a single-array experiment, the use of this method to inves-
tigate CNVs or indels throughout the whole genome is
attractive for investigation of all intellectual disability in
the future. The capacity to examine samples at high resolu-
tion is, however, contingent on hybridization quality: 12%
(31/251) of samples were excluded from high-resolution
analysis because of poor performance, although in some
of these samples large pathogenic variants were readily
detected and more robust lower resolution arrays would
have been sufficient to detect these. Similar to Sharp
et al., we observed that probe performance was related to
the presence of SNPs within the sample underlying the
probes.53 Although improved iterative probe design (to
avoid common SNP-rich regions) will reduce the noise of
high-resolution CGH, some noise is unavoidable as shown
by the fact that, for example, we found a rare SNP under-
lying a series of contiguous probes, suggesting a deletion,
but was due to a pathogenic truncating mutation in
the sample.10 In reporting the CNV calls from this analysis,
it is likely that a significant proportion of the calls reflect
underlying sequence variants and not real copy number
changes. The SNP-associated calls often achieved smaller
log2 ratio deviations than genuine deletions but are none-
theless difficult to tease out in the context of considerable
regional and sample-level variability in log2 ratios.
We found that duplications in Xq28 and Xp11.2 were
detected at relatively high frequency, had family-specific
breakpoints and, in some cases, rearrangement com-
plexity, consistent with the findings of others.30,42 The
reciprocal deletions were not observed. The elevated
frequency of duplications at these loci may reflect features
of genomic architecture predisposing to rearrangement, asThe Americhas been postulated for the complex LCR architecture
surrounding MECP2. In examining sequenced rearrange-
ment breakpoints, we identified an enrichment of GC
content, as has also been noted by others.28,42 Because of
our small sample size, we combined our analysis of dele-
tions and duplications but the underlying mechanisms
may differ for different types of rearrangement, as is sug-
gested by the identification of certain sequence features
that were associated with duplications but not deletions
by Conrad et al.28 The detection of two IL1RAPL1 dele-
tions, in combination with other published reports,54,55
may further support this hypothesis: the absence of recip-
rocal IL1RAPL1 intragenic duplications in the published
literature is intriguing because these would be predicted
to result in the same loss-of-function phenotype as intra-
genic deletions. The mechanism of IL1RAPL1 deletion
may be related to proximity to the fragile site FRAXC and
this mechanism may favor deletion.
Overall, pathogenic duplications were more frequently
identified than deletions, with duplications particularly
dominant at the larger size scale. These observations can
be explained by biological and methodological factors.
Although analysis of de novomutations at four NAHR hot-
spots identified an imbalance in the rates of deletion and
duplication occurrence,56 it is not clear whether there is
an intrinsic bias in rearrangements formed by mitotic
mechanisms, such as microhomology-mediated break-
induced repair, which appear to be the predominant muta-
tional mechanism in this study. Deletions in males on the
X chromosome are frequently lethal or may be associated
with a well-defined clinical syndrome. By comparison,
duplications may be milder in effect that might lead to
their enrichment in the cohort. Consistent with this, pop-
ulation studies in Drosophila indicate that purifying selec-
tion against large variants is weaker for duplications than
for deletions.57 Deletions are also more readily identified
by alternative experimental methods and by low-resolu-
tion array CGH. Notably, the contribution of small dupli-
cations is limited and probably reflects the increased
difficulty in identification.28
The substantial coincidence of pathogenic CNVs with
known XLID-associated genes may indicate that we are
approaching a saturation point of XLID gene discovery.
However, by current estimates ~10% of the genes on the
X chromosome can harbor mutations causing ID and these
are distributed throughout the chromosome.9 Conse-
quently, large deletions or duplications will, in all likeli-
hood, include at least one XLID-associated gene. For
smaller variants, the bias toward known genes is influ-
enced by challenges in interpreting rare variant signifi-
cance. Cautious interpretation of variants is necessary, as
indicated by the fact that resequencing analysis has
revealed that loss of function of ~1% of X chromosome
genes is not associated with a disease phenotype.10 Vari-
ants in the four candidate genes (PTCHD1, FAAH2,
WDR13, and GSPT2) were each identified in only a single
family. Although segregation analysis has provided anan Journal of Human Genetics 87, 173–188, August 13, 2010 183
invaluable aid, as was illustrated by analysis of the IDS
duplication, more conclusive association of a gene with
disease causation requires the identification of multiple
independent cases and would be facilitated by the analysis
of larger cohorts.
The involvement of PTCHD1 in neurological disease is
supported by the report of a partial gene deletion in
a family with autism and by further mutation screening
and functional characterization.21,35 Further analysis also
demonstrates PTCHD1 expression in fetal and adult brain,
largely confined to the cerebellum, and provides additional
evidence for a role of PTCHD1 in neurodevelopmental and
neuropsychiatric disorders.21 PTCHD1 also serves as an
illustration of the emerging genetic overlap between
neurological disorders including ID, autistic spectrum
disorders, and schizophrenia.58,59 One explanation for
this is that abnormalities in the same genes can manifest
as clinically distinct disorders. Alternatively, the observa-
tion may reflect ascertainment bias and clinical overlap
between cohorts. Collection and analysis of large, carefully
phenotyped patient cohorts would facilitate gene
discovery and would also power statistical analysis of the
significance of so-called risk factor associations.
Both theWDR13 and FAAH2 deletions identified are pre-
dicted to render the respective proteins nonfunctional.
WDR13 is a widely expressed WD-repeat containing
protein.60 Although the specific function of WDR13 is
not known, WD-repeat domains are involved in a wide
range of cellular functions and commonly mediate
protein-protein interactions.61 Interestingly, upregulation
of WDR13 in rat hippocampal neurons has been noted
after traumatic injury,62 and we hypothesize that this
role in reactive synaptogenesis may recapitulate a neurode-
velopmental function. FAAH2 encodes a fatty acid amide
hydrolase found in primates and other vertebrates but
not murids.63 Fatty acid hydrolases degrade, and thus inac-
tivate, several endogenous lipid messengers, including
oleamide and the endocannabinoid anandamide.64 The
capacity of FAAH enzymes to modulate neurobehavioral
processes, including pain, sleep pattern, and feeding
behavior, has led to considerable interest in FAAH inhibi-
tors as therapeutic agents (reviewed in 65). The extent of
functional redundancy between the other human fatty
acid amide hydrolase, FAAH, and FAAH2 is unclear. On
the basis of relative expression levels, it has been suggested
that FAAH2 may function predominantly in peripheral
tissues, but FAAH2 is also expressed in the central nervous
system.63 Further studies will be required to determine
whether the partial deletion of FAAH2 underlies the ID
and degenerative eye disease in family 494 or is a coinci-
dental finding.
In family 463, we identified a whole gene duplication of
GSPT2 and confirmed the direct tandem orientation of the
duplicated region. GSPT2 is a single exon gene that has
been postulated to have arisen by retrotransposition of
GSPT1 mRNA.66 GSPT2 is believed to function as a poly-
peptide chain releasing factor during protein synthesis,184 The American Journal of Human Genetics 87, 173–188, August 1thus acting as an important regulator of translational
fidelity. Functional studies in mouse have indicated that
GSPT2, which is widely expressed but relatively abundant
in brain, but not GSPT1 can functionally complement the
orthologous yeast gene SUP35.67,68 GSPT2 upregulation
has been detected in rat in response to in utero treatment
with a neurotoxic agent associated with deficits inmemory
and learning.69 Whether GSPT2 duplication results in
altered expression levels at significant developmental
stages, and whether this may explain the ID phenotype
in family 463, remains to be determined.
Focusing on just the 179 families where we have
completed both X chromosome exon resequencing10 and
high-resolution analysis of the array CGH data, the cause
of disease has been identified in 58 families (32%), which
can be subdivided into 38 (21%) by sequence variants
and 20 (11%) by CNVs. The cause of disease in themajority
of families remains unexplained. A number of explana-
tions should be considered. For example, difficulties in
assigning pathogenicity to coding and noncoding rare
CNVs, and nonsynonymous and synonymous sequence
variants, in the face of considerable benign variation may
account for some of the mutation shortfall. Also, the pres-
ence of variable penetrant alleles and also individuals who
are phenocopies of the disease within pedigrees makes the
interpretation of the data into simple monogenic models
of disease within family complex (AFF2 in family 110).
In addition, both the sequencing and array approaches
are imperfect methodologies and gaps in the coverage
and sequencing annotations may harbor additional
mutations.
Two findings in particular, the noncoding deletion
affecting CUL4B expression in family 506 and the X-auto-
some retrotransposition event in family 306, provide
tantalizing hints toward the contribution of additional
disease mechanisms. The depth of our analysis of noncod-
ing regions by resequencing and array CGH is markedly
inferior to that of coding regions. Analysis of noncoding
variants is also complicated by our relatively limited
knowledge of functional noncoding elements and CNV
interpretation can be clouded by long-range position
effects.70–73 In the future, the increasing availability of
whole-genome sequences, genome-wide expression data,
and computational tools will aid our ability to detect and
interpret noncoding mutations.
The X chromosome has been reported to be enriched as
both a donor and recipient of retrotransposition events,
perhaps indicating that this mechanism may contribute
disproportionately to X-linked disease.74 Retrotransposi-
tion events would be inefficiently detected by PCR-based
sequencing and probe-based analysis strategies employed
thus far. The result in family 306 also brings into question
the contribution of non-X-linked causes in pedigrees with
segregation patterns that are classically associated with
X-linked disease. In family 306, the disease tracks in the
family with the presence of an insertion located on
chromosome 7p22.2 and linkage analysis excludes the3, 2010
X chromosome despite a pedigree with several affected
males and unaffected female ‘‘carriers.’’ The cohort
analyzed were all familial cases where males were more
severely affected than females, suggesting X-linked inheri-
tance. The distribution of resolved to unresolved families is
skewed toward the larger pedigrees but there remains
a substantial shortfall of mutations in some of the largest
families. The question of whether all families with disease
are truly monogenic with identifiable high penetrance
mutations or whether other modes of inheritance should
be considered remains to be answered. In the meantime,
this work shows that where there are two or more males
with intellectual impairment in a family, high-resolution
array CGH will identify the cause of disease in ~10% of
cases. This adds to the recently established data that
sequence analysis for coding mutations in exons on the
X chromosome will yield results in a further ~20% of
cases.10 A comprehensive assessment of the total contribu-
tion of X-linked disease genes to familial ID inmales awaits
the power of whole genome next generation sequence
analysis75–77 and the development of robust methods to
determine pathogenic significance.Supplemental Data
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